Cargando…

102. Efficacy and Effectiveness of High-Dose Influenza Vaccine in Older Adults by Age and Seasonal Characteristics: An Updated Systematic Review and Meta-Analysis

BACKGROUND: High-dose influenza vaccine (HD-IIV) has been used extensively in older adults since its approval in 2009. Studies comparing HD-IIV to standard-dose influenza vaccines (SD-IIV) have demonstrated protection beyond influenza, including reduction of outcomes like cardiorespiratory and all-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jason K, Lam, Gary K, Vaisman, Rolan, Yin, Kevin J, Seet, Bruce T, Loiacono, Matthew M, Samson, Sandrine I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751930/
http://dx.doi.org/10.1093/ofid/ofac492.180
_version_ 1784850593547812864
author Lee, Jason K
Lam, Gary K
Vaisman, Rolan
Yin, Kevin J
Seet, Bruce T
Loiacono, Matthew M
Samson, Sandrine I
author_facet Lee, Jason K
Lam, Gary K
Vaisman, Rolan
Yin, Kevin J
Seet, Bruce T
Loiacono, Matthew M
Samson, Sandrine I
author_sort Lee, Jason K
collection PubMed
description BACKGROUND: High-dose influenza vaccine (HD-IIV) has been used extensively in older adults since its approval in 2009. Studies comparing HD-IIV to standard-dose influenza vaccines (SD-IIV) have demonstrated protection beyond influenza, including reduction of outcomes like cardiorespiratory and all-cause hospitalizations. This study is an update of previously-conducted reviews of the relative vaccine efficacy/effectiveness (rVE) of HD-IIV vs. SD-IIV in adults ≥65 years against influenza-associated outcomes from 2009-2020, with sub-analyses by seasonal and recipient characteristics. METHODS: An updated systematic review and meta-analysis was conducted for studies assessing the rVE of HD-IIV against probable/laboratory-confirmed influenza-like illness (ILI), emergency department (ED) and/or hospital admissions in adults ≥65 years. Results from individual seasons – stratified by outcome, subject characteristics, and influenza season, were meta-analyzed to estimate pooled rVEs of HD-IIV. RESULTS: 19 studies from 11 consecutive seasons with over 45 million HD-IIV or SD-IIV recipients were meta-analyzed. Overall, HD-IIV demonstrated improved protection vs. SD-IIV against ILI (rVE=14.3%, 95%CI:4.2-23.3%), HD-IIV was more effective at preventing hospital/ED visits due to influenza (rVE=10.4%, 95%CI:6.8-13.9%), and hospitalizations due to influenza (rVE=11.2%, 95%CI:7.4-14.8%), pneumonia (rVE=27.3%, 95%CI:15.3-37.6%); pneumonia and influenza (rVE=13.4%, 95%CI:7.3-19.2%); respiratory (rVE=14.3%, 95%CI:8.5-20.0%), cardiovascular (rVE=13.1%, 95%CI:10.5-15.7%), and cardiorespiratory events (rVE=17.9%, 95%CI:15.0-20.8%); and all-causes (rVE=8.4%, 95%CI:5.7-11.0%). Pooled rVEs were similar in sub-analyses by dominant strain, antigenic match, and study type/setting. While all adults 65+ benefited from the use of HD-IIV, age-stratified analyses of the rVE of HD-IIV suggested additional relative benefit with increasing age. CONCLUSION: Evidence over 11 consecutive influenza seasons from both randomized and observational studies suggests HD-IIV was consistently more effective than SD-IIV at reducing influenza and associated serious outcomes irrespective of recipient age and characteristics of the influenza season. DISCLOSURES: Jason K. Lee, MS, MBiotech, Sanofi: Employee|Sanofi: Stocks/Bonds Gary K. Lam, PharmD, RPh, Sanofi: Employee Rolan Vaisman, PharmD, RPh, Sanofi: Employee Kevin J. Yin, MD, MPH, PhD, Sanofi: Employee|Sanofi: Stocks/Bonds Bruce T. Seet, PhD, MBA, Sanofi: Employee|Sanofi: Stocks/Bonds Matthew M. Loiacono, PhD, MSc, Sanofi: Employee|Sanofi: Stocks/Bonds Sandrine I. Samson, PhD, Sanofi: Employee|Sanofi: Stocks/Bonds.
format Online
Article
Text
id pubmed-9751930
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-97519302022-12-16 102. Efficacy and Effectiveness of High-Dose Influenza Vaccine in Older Adults by Age and Seasonal Characteristics: An Updated Systematic Review and Meta-Analysis Lee, Jason K Lam, Gary K Vaisman, Rolan Yin, Kevin J Seet, Bruce T Loiacono, Matthew M Samson, Sandrine I Open Forum Infect Dis Abstracts BACKGROUND: High-dose influenza vaccine (HD-IIV) has been used extensively in older adults since its approval in 2009. Studies comparing HD-IIV to standard-dose influenza vaccines (SD-IIV) have demonstrated protection beyond influenza, including reduction of outcomes like cardiorespiratory and all-cause hospitalizations. This study is an update of previously-conducted reviews of the relative vaccine efficacy/effectiveness (rVE) of HD-IIV vs. SD-IIV in adults ≥65 years against influenza-associated outcomes from 2009-2020, with sub-analyses by seasonal and recipient characteristics. METHODS: An updated systematic review and meta-analysis was conducted for studies assessing the rVE of HD-IIV against probable/laboratory-confirmed influenza-like illness (ILI), emergency department (ED) and/or hospital admissions in adults ≥65 years. Results from individual seasons – stratified by outcome, subject characteristics, and influenza season, were meta-analyzed to estimate pooled rVEs of HD-IIV. RESULTS: 19 studies from 11 consecutive seasons with over 45 million HD-IIV or SD-IIV recipients were meta-analyzed. Overall, HD-IIV demonstrated improved protection vs. SD-IIV against ILI (rVE=14.3%, 95%CI:4.2-23.3%), HD-IIV was more effective at preventing hospital/ED visits due to influenza (rVE=10.4%, 95%CI:6.8-13.9%), and hospitalizations due to influenza (rVE=11.2%, 95%CI:7.4-14.8%), pneumonia (rVE=27.3%, 95%CI:15.3-37.6%); pneumonia and influenza (rVE=13.4%, 95%CI:7.3-19.2%); respiratory (rVE=14.3%, 95%CI:8.5-20.0%), cardiovascular (rVE=13.1%, 95%CI:10.5-15.7%), and cardiorespiratory events (rVE=17.9%, 95%CI:15.0-20.8%); and all-causes (rVE=8.4%, 95%CI:5.7-11.0%). Pooled rVEs were similar in sub-analyses by dominant strain, antigenic match, and study type/setting. While all adults 65+ benefited from the use of HD-IIV, age-stratified analyses of the rVE of HD-IIV suggested additional relative benefit with increasing age. CONCLUSION: Evidence over 11 consecutive influenza seasons from both randomized and observational studies suggests HD-IIV was consistently more effective than SD-IIV at reducing influenza and associated serious outcomes irrespective of recipient age and characteristics of the influenza season. DISCLOSURES: Jason K. Lee, MS, MBiotech, Sanofi: Employee|Sanofi: Stocks/Bonds Gary K. Lam, PharmD, RPh, Sanofi: Employee Rolan Vaisman, PharmD, RPh, Sanofi: Employee Kevin J. Yin, MD, MPH, PhD, Sanofi: Employee|Sanofi: Stocks/Bonds Bruce T. Seet, PhD, MBA, Sanofi: Employee|Sanofi: Stocks/Bonds Matthew M. Loiacono, PhD, MSc, Sanofi: Employee|Sanofi: Stocks/Bonds Sandrine I. Samson, PhD, Sanofi: Employee|Sanofi: Stocks/Bonds. Oxford University Press 2022-12-15 /pmc/articles/PMC9751930/ http://dx.doi.org/10.1093/ofid/ofac492.180 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstracts
Lee, Jason K
Lam, Gary K
Vaisman, Rolan
Yin, Kevin J
Seet, Bruce T
Loiacono, Matthew M
Samson, Sandrine I
102. Efficacy and Effectiveness of High-Dose Influenza Vaccine in Older Adults by Age and Seasonal Characteristics: An Updated Systematic Review and Meta-Analysis
title 102. Efficacy and Effectiveness of High-Dose Influenza Vaccine in Older Adults by Age and Seasonal Characteristics: An Updated Systematic Review and Meta-Analysis
title_full 102. Efficacy and Effectiveness of High-Dose Influenza Vaccine in Older Adults by Age and Seasonal Characteristics: An Updated Systematic Review and Meta-Analysis
title_fullStr 102. Efficacy and Effectiveness of High-Dose Influenza Vaccine in Older Adults by Age and Seasonal Characteristics: An Updated Systematic Review and Meta-Analysis
title_full_unstemmed 102. Efficacy and Effectiveness of High-Dose Influenza Vaccine in Older Adults by Age and Seasonal Characteristics: An Updated Systematic Review and Meta-Analysis
title_short 102. Efficacy and Effectiveness of High-Dose Influenza Vaccine in Older Adults by Age and Seasonal Characteristics: An Updated Systematic Review and Meta-Analysis
title_sort 102. efficacy and effectiveness of high-dose influenza vaccine in older adults by age and seasonal characteristics: an updated systematic review and meta-analysis
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751930/
http://dx.doi.org/10.1093/ofid/ofac492.180
work_keys_str_mv AT leejasonk 102efficacyandeffectivenessofhighdoseinfluenzavaccineinolderadultsbyageandseasonalcharacteristicsanupdatedsystematicreviewandmetaanalysis
AT lamgaryk 102efficacyandeffectivenessofhighdoseinfluenzavaccineinolderadultsbyageandseasonalcharacteristicsanupdatedsystematicreviewandmetaanalysis
AT vaismanrolan 102efficacyandeffectivenessofhighdoseinfluenzavaccineinolderadultsbyageandseasonalcharacteristicsanupdatedsystematicreviewandmetaanalysis
AT yinkevinj 102efficacyandeffectivenessofhighdoseinfluenzavaccineinolderadultsbyageandseasonalcharacteristicsanupdatedsystematicreviewandmetaanalysis
AT seetbrucet 102efficacyandeffectivenessofhighdoseinfluenzavaccineinolderadultsbyageandseasonalcharacteristicsanupdatedsystematicreviewandmetaanalysis
AT loiaconomatthewm 102efficacyandeffectivenessofhighdoseinfluenzavaccineinolderadultsbyageandseasonalcharacteristicsanupdatedsystematicreviewandmetaanalysis
AT samsonsandrinei 102efficacyandeffectivenessofhighdoseinfluenzavaccineinolderadultsbyageandseasonalcharacteristicsanupdatedsystematicreviewandmetaanalysis